Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clearside Biomedi (CLSD)

Clearside Biomedi (CLSD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,046
  • Shares Outstanding, K 37,760
  • Annual Sales, $ 30 K
  • Annual Income, $ -82,820 K
  • 60-Month Beta -0.34
  • Price/Sales 1,409.71
  • Price/Cash Flow N/A
  • Price/Book 3.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate 0.01
  • Low Estimate -0.17
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +85.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.75 +54.67%
on 10/21/19
1.39 -16.55%
on 11/04/19
+0.39 (+50.65%)
since 10/11/19
3-Month
0.56 +107.14%
on 08/28/19
1.39 -16.55%
on 11/04/19
-0.16 (-12.12%)
since 08/09/19
52-Week
0.56 +107.14%
on 08/28/19
1.92 -39.58%
on 11/23/18
-0.68 (-36.96%)
since 11/09/18

Most Recent Stories

More News
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -6.25% and 182.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

CLSD : 1.16 (+1.75%)
Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate Update

- Recent Partnerships Support the Broad Applicability of Suprachoroidal Space Injection Platform to Potentially Treat Multiple Ocular Diseases -

CLSD : 1.16 (+1.75%)
Clearside Biomedical to Report Third Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, November 6, 2019

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 1.16 (+1.75%)
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector(TM) in AAV Gene Therapy Delivery

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 1.16 (+1.75%)
RGNX : 38.52 (-3.41%)
Bausch Health Licenses Clearside Biomedical's XIPERE(TM) (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis

NDA Resubmission to the FDA Expected to Occur in the First Quarter of 2020

CLSD : 1.16 (+1.75%)
Clearside Biomedical Suprachoroidal Injection Platform Featured in Multiple Presentations at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 1.16 (+1.75%)
Ocular Drug Delivery Technology Market : Discussion Of Market Drivers, Key Vendors And Challenges With Forecast To 2024

Ocular drug delivery refers to the treatment of ophthalmic diseases. Ophthalmic diseases affect various parts of the eye anatomy, are specified on the basis of their position namely, anterior segment and...

CLSD : 1.16 (+1.75%)
NVS : 88.63 (+0.29%)
PFE : 36.93 (-0.32%)
VRX.TO : 30.80 (-3.33%)
Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 1.16 (+1.75%)
Clearside Biomedical Featured at Multiple European Scientific Retinal Congresses

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 1.16 (+1.75%)
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 38.52 (-3.41%)
CLSD : 1.16 (+1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade CLSD with:

Business Summary

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious...

See More

Key Turning Points

2nd Resistance Point 1.21
1st Resistance Point 1.19
Last Price 1.16
1st Support Level 1.14
2nd Support Level 1.11

See More

52-Week High 1.92
Fibonacci 61.8% 1.40
Fibonacci 50% 1.24
Last Price 1.16
Fibonacci 38.2% 1.08
52-Week Low 0.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar